ALM014
Depression
Pivotal BA/BEActive
Key Facts
About Almatica Pharma
Almatica Pharma, a subsidiary of the global generics firm Alvogen, is a specialty CNS-focused pharmaceutical company developing novel treatments for psychiatric and neurological disorders. Founded in 2008 and headquartered in Pittsburgh, the company leverages a lean structure and end-to-end R&D capabilities to advance a pipeline of several drug candidates, primarily in mid-to-late-stage clinical development for depression and anxiety. As a private entity, it benefits from the commercial infrastructure and expertise of its parent company while targeting significant unmet needs in the mental health therapeutic area with innovative medicines and patient support programs.
View full company profileTherapeutic Areas
Other Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Depression Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| Depression Study | Sun Valley Research Center | Not Disclosed |
| eTNS Platform | NeuroSigma | Unknown |
| ALM003 | Almatica Pharma | Phase 3 |
| NRCT-101SR | Neurocentria | Phase 2b/3 |
| Starstim for Depression | Neuroelectrics | Phase 1/2 |
| Depression Biomarkers | Paradise Genomics | Discovery |
| Home-tDCS Depression Trial | Soterix Medical | N/A (Device-enabled trial) |
| BPL-003 | AtaiBeckley | Phase 2 |
| VLS-01 | AtaiBeckley | Phase 2 |
| NC-2800 | Nippon Chemiphar | Phase 2a |